Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity

Andrea Ravelli, James M. Reuben, Francesco Lanza, Simone Anfossi, Maria Rosa Cappelletti, Laura Zanotti, Angela Gobbi, Manuela Milani, Daniele Spada, Paolo Pedrazzoli, Massimo Martino, Alberto Bottini, Daniele Generali

Research output: Contribution to journalArticle

Abstract

Because its original use as a treatment for hematologic disease, more recently immunotherapy has emerged as a novel effective therapeutic strategy for solid malignancies, such as melanoma and prostate carcinoma. For breast carcinoma, an immunologic therapeutic approach has not been well evaluated, even though there is evidence to suggest it would be a successful novel strategy, especially taking into account the high mortality rate of the most aggressive variants of this heterogeneous disease. Here, we briefly describe the most recently awarded immune-based therapies with a consolidated or potential implication for the treatment of solid malignancies. We focus on immune checkpoints and on the clinical potential of their abrogation, with a further overview of novel vaccine-based approaches and the most relevant immunotherapeutic techniques. We aim to provide an exhaustive review of the most promising immune-therapeutic agents that may have implications for breast cancer treatment.

Original languageEnglish
Pages (from-to)689-702
Number of pages14
JournalExpert Review of Anticancer Therapy
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Immunotherapy
Breast Neoplasms
Therapeutics
Hematologic Diseases
Prostate
Melanoma
Neoplasms
Vaccines
Carcinoma
Mortality

Keywords

  • adoptive T-cell therapy
  • breast cancer
  • breast cancer therapy
  • breast cancer vaccine
  • immune checkpoint blockade
  • ipilimumab
  • pidilizumab
  • tremelimumab
  • vaccination

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Medicine(all)

Cite this

Ravelli, A., Reuben, J. M., Lanza, F., Anfossi, S., Cappelletti, M. R., Zanotti, L., ... Generali, D. (2015). Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity. Expert Review of Anticancer Therapy, 15(6), 689-702. https://doi.org/10.1586/14737140.2015.1042864

Immune-related strategies driving immunotherapy in breast cancer treatment : A real clinical opportunity. / Ravelli, Andrea; Reuben, James M.; Lanza, Francesco; Anfossi, Simone; Cappelletti, Maria Rosa; Zanotti, Laura; Gobbi, Angela; Milani, Manuela; Spada, Daniele; Pedrazzoli, Paolo; Martino, Massimo; Bottini, Alberto; Generali, Daniele.

In: Expert Review of Anticancer Therapy, Vol. 15, No. 6, 01.06.2015, p. 689-702.

Research output: Contribution to journalArticle

Ravelli, A, Reuben, JM, Lanza, F, Anfossi, S, Cappelletti, MR, Zanotti, L, Gobbi, A, Milani, M, Spada, D, Pedrazzoli, P, Martino, M, Bottini, A & Generali, D 2015, 'Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity', Expert Review of Anticancer Therapy, vol. 15, no. 6, pp. 689-702. https://doi.org/10.1586/14737140.2015.1042864
Ravelli, Andrea ; Reuben, James M. ; Lanza, Francesco ; Anfossi, Simone ; Cappelletti, Maria Rosa ; Zanotti, Laura ; Gobbi, Angela ; Milani, Manuela ; Spada, Daniele ; Pedrazzoli, Paolo ; Martino, Massimo ; Bottini, Alberto ; Generali, Daniele. / Immune-related strategies driving immunotherapy in breast cancer treatment : A real clinical opportunity. In: Expert Review of Anticancer Therapy. 2015 ; Vol. 15, No. 6. pp. 689-702.
@article{3648671d35084f0dbcde8fa5b5ee75a5,
title = "Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity",
abstract = "Because its original use as a treatment for hematologic disease, more recently immunotherapy has emerged as a novel effective therapeutic strategy for solid malignancies, such as melanoma and prostate carcinoma. For breast carcinoma, an immunologic therapeutic approach has not been well evaluated, even though there is evidence to suggest it would be a successful novel strategy, especially taking into account the high mortality rate of the most aggressive variants of this heterogeneous disease. Here, we briefly describe the most recently awarded immune-based therapies with a consolidated or potential implication for the treatment of solid malignancies. We focus on immune checkpoints and on the clinical potential of their abrogation, with a further overview of novel vaccine-based approaches and the most relevant immunotherapeutic techniques. We aim to provide an exhaustive review of the most promising immune-therapeutic agents that may have implications for breast cancer treatment.",
keywords = "adoptive T-cell therapy, breast cancer, breast cancer therapy, breast cancer vaccine, immune checkpoint blockade, ipilimumab, pidilizumab, tremelimumab, vaccination",
author = "Andrea Ravelli and Reuben, {James M.} and Francesco Lanza and Simone Anfossi and Cappelletti, {Maria Rosa} and Laura Zanotti and Angela Gobbi and Manuela Milani and Daniele Spada and Paolo Pedrazzoli and Massimo Martino and Alberto Bottini and Daniele Generali",
year = "2015",
month = "6",
day = "1",
doi = "10.1586/14737140.2015.1042864",
language = "English",
volume = "15",
pages = "689--702",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Immune-related strategies driving immunotherapy in breast cancer treatment

T2 - A real clinical opportunity

AU - Ravelli, Andrea

AU - Reuben, James M.

AU - Lanza, Francesco

AU - Anfossi, Simone

AU - Cappelletti, Maria Rosa

AU - Zanotti, Laura

AU - Gobbi, Angela

AU - Milani, Manuela

AU - Spada, Daniele

AU - Pedrazzoli, Paolo

AU - Martino, Massimo

AU - Bottini, Alberto

AU - Generali, Daniele

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Because its original use as a treatment for hematologic disease, more recently immunotherapy has emerged as a novel effective therapeutic strategy for solid malignancies, such as melanoma and prostate carcinoma. For breast carcinoma, an immunologic therapeutic approach has not been well evaluated, even though there is evidence to suggest it would be a successful novel strategy, especially taking into account the high mortality rate of the most aggressive variants of this heterogeneous disease. Here, we briefly describe the most recently awarded immune-based therapies with a consolidated or potential implication for the treatment of solid malignancies. We focus on immune checkpoints and on the clinical potential of their abrogation, with a further overview of novel vaccine-based approaches and the most relevant immunotherapeutic techniques. We aim to provide an exhaustive review of the most promising immune-therapeutic agents that may have implications for breast cancer treatment.

AB - Because its original use as a treatment for hematologic disease, more recently immunotherapy has emerged as a novel effective therapeutic strategy for solid malignancies, such as melanoma and prostate carcinoma. For breast carcinoma, an immunologic therapeutic approach has not been well evaluated, even though there is evidence to suggest it would be a successful novel strategy, especially taking into account the high mortality rate of the most aggressive variants of this heterogeneous disease. Here, we briefly describe the most recently awarded immune-based therapies with a consolidated or potential implication for the treatment of solid malignancies. We focus on immune checkpoints and on the clinical potential of their abrogation, with a further overview of novel vaccine-based approaches and the most relevant immunotherapeutic techniques. We aim to provide an exhaustive review of the most promising immune-therapeutic agents that may have implications for breast cancer treatment.

KW - adoptive T-cell therapy

KW - breast cancer

KW - breast cancer therapy

KW - breast cancer vaccine

KW - immune checkpoint blockade

KW - ipilimumab

KW - pidilizumab

KW - tremelimumab

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=84930467798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930467798&partnerID=8YFLogxK

U2 - 10.1586/14737140.2015.1042864

DO - 10.1586/14737140.2015.1042864

M3 - Article

C2 - 25927868

AN - SCOPUS:84930467798

VL - 15

SP - 689

EP - 702

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 6

ER -